Fayyaz Mujtaba is leaving Wellington Management, the sole subadvisor of Hartford Healthcare, and will no longer serve as a manager of this strategy, effective immediately. His departure does not affect the strategy’s Above Average People rating or its Morningstar Medalist Rating of Silver or Bronze, depending on share class.
Hartford Healthcare C HGHCX
- NAV / 1-Day Return 25.50 / −0.35 %
- Total Assets 1.1 Bil
-
Adj. Expense Ratio
- Expense Ratio 2.050%
- Distribution Fee Level Average
- Share Class Type Level Load
- Category Health
- Investment Style Large Growth
- Min. Initial Investment 2,000
- Status Open
- TTM Yield —
- Turnover 32%
USD | NAV as of Apr 18, 2024 | 1-Day Return as of Apr 18, 2024, 10:16 PM GMT+0
Morningstar’s Analysis HGHCX
Will HGHCX outperform in future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
Parent Pillar
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 43.3
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
---|---|---|---|
Eli Lilly and Co | 10.89 | 128.1 Mil | Healthcare |
UnitedHealth Group Inc | 6.78 | 79.8 Mil | Healthcare |
Merck & Co Inc | 6.35 | 74.6 Mil | Healthcare |
Danaher Corp | 3.90 | 45.9 Mil | Healthcare |
Stryker Corp | 2.83 | 33.3 Mil | Healthcare |
Boston Scientific Corp | 2.80 | 32.9 Mil | Healthcare |
Thermo Fisher Scientific Inc | 2.52 | 29.7 Mil | Healthcare |
HCA Healthcare Inc | 2.52 | 29.7 Mil | Healthcare |
AbbVie Inc | 2.39 | 28.1 Mil | Healthcare |
Vertex Pharmaceuticals Inc | 2.32 | 27.3 Mil | Healthcare |